Toggle menu

Garfield-VTE

Start date:
May 2015
End date:
December 2019
Co-ordinated by:
Thrombosis Research Institute UK
Main trial site:
RIE

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world.

Aim

The study objectives are to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic outcomes in patients with treated acute VTE (DVT and PE) in the real-world setting.

Trial Design

Global, prospective, observational, multi-centre VTE registry to be conducted in sequential cohorts.

In order to observe temporal trends in management of VTE a minimum of 2 cohorts will be recruited. Recruitment into the second (or subsequent cohorts) will commence when recruitment is completed into the first or previous cohort. It is estimated that each cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis.

Cohort One

5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months

Cohort Two

A further 5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months

Eligibility criteria

Inclusion Criteria

  1. Written informed consent
  2. Age 18 years and over
  3. Treated first time or recurrent DVT (lower or upper extremity), PE alone or overlapping DVT and PE confirmed by appropriate diagnostic methods (patients must be assessed for eligibility within 30 days of diagnosis)
  4. Patients included with recurrent VTE must have completed treatment for the previous VTE episode

Exclusion Criteria

  1. Patients for whom long-term follow up is not envisaged within the enrolling hospital or the associated primary care physician
  2. Patients participating in an interventional study that dictates treatments, visit frequency, or diagnostic procedures
  3. Patients with only superficial vein thrombosis (SVT)

Local PI

Dr Ann Lockman

Consultant in Acute Medicine

Research Team

Julia Grahamslaw

Lead Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

More EMERGE Trials

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Assisting in identifying patients with Humeral shaft fractures in the ED by screening.

Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.

Read more

HU-FIX